Picture4We are involved in a number of research collaborations with major pharmaceutical companies.  These range from early stage research establishing target tractability through to late lead optimisation programs. We value close co-operation with our collaborators to ensure the combined strengths of the partners are most effectively deployed to deliver drug candidates.

Current disclosed collaborations include

  • Servier, two development stage collaborations on Bcl-2 family of proteins and two further research collaborations on undisclosed oncology targets
  • Lundbeck, a research collaboration targetting LRRK2
  • Asahi Kasei Pharmaceuticals, a research collaboration targetting Rheumatoid Arthritis
  • Taisho Pharmaceuticals Co., Ltd, a research collaboration targetting an undisclosed target


Latest News

Vernalis plc receives a $2 million milestone payment from one of its drug discovery collaborations

Vernalis plc announced today that it has received a $2m milestone under one of its existing research collaborations to discover novel small molecules against an undisclosed target utilising Vernalis' fragment and structure-based drug discovery platform.

Read more ...

Product Pipeline

For more information on our pipeline, click below to visit Vernalis plc

Commercial Pipeline

Comm-thumbnailExplore the pipeline ...


NCE Pipeline

NCE-thumbnailExplore the pipeline ...


Contact Vernalis Research

T: (0)1223 895555
F: (0)1223 895556

Contact information
Maps and directions
Contact form

Fact Sheet

For more information on Vernalis, click on the below image to download a copy of our fact sheet

Vernalis Factsheet May 2015 Page 1